Peter W. Tuerk

Peter W. Tuerk

Auto-generated profile, based on publicly available information

Peter W. Tuerk

Medical University of South Carolina

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2010 in Journal of Traumatic Stress
Verified
Journal Article
Closed access
PDF file
PTPeter W. Tuerk
Peter W. Tuerk
MYMatthew Yoder
Matthew Yoder
KRKenneth J. Ruggiero
Kenneth J. Ruggiero
DGDaniel F. Gros
Daniel F. Gros
RARon Acierno
Ron Acierno

1 April 2011 in Journal of Anxiety Disorders
Verified
Journal Article
Closed access
PTPeter W. Tuerk
Peter W. Tuerk
MYMatthew Yoder
Matthew Yoder
AGAnouk Grubaugh
Anouk Grubaugh
HMHugh Myrick
Hugh Myrick
MHMark Hamner
Mark Hamner
RARon Acierno
Ron Acierno

1 October 2018 in FOCUS
Verified
Journal Article
Closed access
PTPeter W. Tuerk
Peter W. Tuerk
SKStephanie M. Keller
Stephanie M. Keller
RARon Acierno
Ron Acierno

15 February 2018 in Cognitive Behaviour Therapy
Verified
Journal Article
Closed access
PTPeter W. Tuerk
Peter W. Tuerk
BWBethany C. Wangelin
Bethany C. Wangelin
MPMark B. Powers
Mark B. Powers
JSJasper A. J. Smits
Jasper A. J. Smits
RARonald ettore Acierno
Ronald ettore Acierno
MHMark B. Hamner
Mark B. Hamner
The alpha-2 adrenergic receptor antagonist, yohimbine, can facilitate fear extinction in animals and humans. One potential mechanism is increased noradrenergic activity and associated arousal in the presence of conditioned stimuli. Accordingly, yohimbine might augment prolonged exposure (PE) therapy for posttraumatic stress disorder (PTSD), where heightened exposure-oriented arousal is a theorized driver and empirical predictor of treatment success. A double-blind placebo-controlled randomized trial (NCT 01031979) piloted yohimbine augmentation in 26 males with combat-related PTSD. Participants were given one-time dose of yohimbine or placebo prior to the first imaginal exposure. Subsequently, both arms completed standard PE. The primary outcome was trauma-cued heart-rate reactivity a week after the drug/exposure visit, a highly specified, objective measure sensitive to incremental change. Secondary outcomes included arousal during the drug/exposure visit and slope of distress, PTSD, and depression over the course of PE. Consistent with hypothesis, yohimbine led to higher objective and subjective arousal during the drug/exposure visit and to lower trauma-cued heart-rate reactivity one-week later. One dose of yohimbine also led to greater between-session habituation and more rapid improvement on depression, but not PTSD, over the course of care. Results of this controlled pilot indicate support for continued investigation of yohimbine-augmented exposure therapy for PTSD.

1 May 2008 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
PTPeter W. Tuerk
Peter W. Tuerk
MMMartina Mueller
Martina Mueller
LELeonard E. Egede
Leonard E. Egede
OBJECTIVE—Researchers have only just begun to investigate physician-related effects on medical outcomes. Such research is necessary for developing empirically informed practice guidelines and policy. The primary goal of this study was to investigate whether glucose management in type 2 diabetes varies by randomly assigned physicians over the course of a year in treatment. A second goal of the study was to investigate whether physician-related effects vary across differential patient characteristics. A tertiary goal was to investigate potential patient-level effects on glucose management. RESEARCH DESIGN AND METHODS—Hierarchical linear models were used to investigate A1C among 1,381 patients, nested within 42 randomly assigned primary care physicians at a Veterans Affairs medical center in the southeastern U.S. The primary outcome measure was change in A1C over the course of 1 year in treatment. On average, each study physician had 33 patients with diabetes. RESULTS—Overall, physician-related factors were associated with statistically significant but modest variability in A1C change (2%), whereas patient-level factors accounted for the majority of variation in A1C change (98%). Physician effects varied by patient characteristics, mattering more for black patients, patients aged 65 years, and patients whose glucose management improved over the treatment year. CONCLUSIONS—The results of this study indicate that differential physician effects have minimal impact on glycemic control. Results suggest that it is logical to support policies encouraging the development of patient-level behavioral interventions because that is the level that accounts for the majority of variance in glycemic control.

1 July 2009 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
PTPeter W. Tuerk
Peter W. Tuerk
AGAnouk L. Grubaugh
Anouk L. Grubaugh
MHMark B. Hamner
Mark B. Hamner
EFEdna B. Foa
Edna B. Foa